Seeking participants for research study on new HIV medication for treatment and prevention

Researchers are interested in evaluating a new HIV medication that will be used for both HIV treatment and HIV prevention. You must be 18 to 65 years old and HIV negative.

The name of the medication is GSK 1265744 -- or GSK 744, for short. This study is recruiting people who are HIV negative to ensure that the drug is safe for people who are HIV negative and that the drug causes little or no side effects. Researchers also want to learn more about how the drug moves through the body and how people feel about taking the medication.

This study will last approximately one and a half years. Participants will receive oral tablets of GSK744 or placebo for four weeks, followed by one week without medication. Participants who have little or no side effects with the oral tablets will then be given the medication or placebo via two intramuscular injections (shot) in the gluteal (butt) muscles at three time points every twelve weeks over a six-month time period. The injectable form of the drug is long-acting. Participants will have nineteen study visits over the course of 81 weeks.   

You may be eligible if:

  • You are between the ages of 18 and 65 years old
  • You are HIV negative
  • You are in good health
  • You are able to swallow pills and are willing to receive intramuscular injections
  • You are not pregnant, breastfeeding, or planning on becoming pregnant for 2 years.
  • You do not have cardiovascular disease, liver disease, or any skin disease

Participants will be eligible to earn $50 per visit and up to $950 for completing all study visits.

If interested, please reply to with the following information:

  • Name
  • E-mail address
  • Phone number
  • Best time to be contacted

This study titled "A Phase IIa Study to Evaluate the Safety and Pharmacokinetics of the Investigational Injectable HIV Integrase inhibitor, GSK1265744, in HIV-uninfected Men and Women” was approved by the UNC Biomedical IRB# 14-1309, initial approval date July 16, 2014.

Filed under: